Comorbid psychiatric and substance abuse disorders: Recent treatment research

Substance Abuse

Volumn 29, Issue 3, 2008, Pages 51-63

  Riggs, Paula ^a   Levin, Frances ^b   Green, Alan I ^c   Vocci, Frank ^d  

^a UNIVERSITY OF COLORADO   (United States)

^b NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^c DARTMOUTH MEDICAL SCHOOL   (United States)

^d NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

Adolescence; Attention deficit hyperactivity disorder; Comorbidity; Depression; Schizophrenia

Indexed keywords

ACAMPROSATE; AMFEBUTAMONE; AMPHETAMINE DERIVATIVE; ATOMOXETINE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; COCAINE; DISULFIRAM; FLUOXETINE; LITHIUM CARBONATE; METHYLPHENIDATE; MODAFINIL; NALTREXONE; NEUROLEPTIC AGENT; PEMOLINE; PLACEBO; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT;

ALCOHOLISM; ATTENTION DEFICIT DISORDER; BIPOLAR DISORDER; CANNABIS ADDICTION; CLINICAL TRIAL; COCAINE DEPENDENCE; COMORBIDITY; CONDUCT DISORDER; DEPRESSION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG DEPENDENCE; DRUG DEPENDENCE TREATMENT; DRUG USE; GENETIC ASSOCIATION; GENETIC RISK; HEALTH CARE COST; HIGH RISK POPULATION; HUMAN; LEARNING DISORDER; MAJOR DEPRESSION; MEDICAL RESEARCH; MENTAL DISEASE; METHADONE TREATMENT; MOOD DISORDER; NEGLECT; NEUROBIOLOGY; OPPOSITIONAL DEFIANT DISORDER; REVIEW; SCHIZOPHRENIA; SUBSTANCE ABUSE; UNSPECIFIED SIDE EFFECT; ADDICTION; ADOLESCENT; DRUG THERAPY; METHODOLOGY;

ADOLESCENT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; DRUG THERAPY; HUMANS; SCHIZOPHRENIA; SUBSTANCE-RELATED DISORDERS;

EID: 58149358827     PISSN: 08897077     EISSN: 15470164     Source Type: Journal    
DOI: 10.1080/08897070802218794     Document Type: Review

References (78)

1. Johnson B, Cloninger C, Roache J, Bordnick P, Ruiz P: Age of onset as a discriminator between alcoholic subtypes in a treatment-seeking population. Am J Addict 2000;1:17-27.
2. Costello E, Erkanli A, Federman E, Angold A: Development of psychiatric comorbidity with substance misuse and in adolescents: effects of timing and sex. J Clin Child Psychiatry 1999;28:298-311.
3. Kandel DB, Johnson JG, Bird H, Weissman M, Goodman SH, Lahey BB, Regier DA, Schwab-Stone ME: Psychiatric comorbidity among adolescents with substance abuse disorders: Findings from the MECA study. J Am Acad Child Adolesc Psychiatry 1999;38:693-699.
4. Weinberg N, Rahdert E, Colliver J, Glantz, M: Adolescent substance abuse: a review of the past 10 years. Am J Acad Child Adolesc Psychiatry 1998;37:252-259.
5. Waxmonsky JG, Wilens TE: Pharmacotherapy of adolescent substance use disorders: a review of the literature. J Child Adolesc Psychopharmacol 2005;15: 810-825.
6. Lewinsohn PM, Hops H, Roberts RE, Seeley JR, Andrews JA: Adolescent psychopathology, I: prevalence and incidence of depression and other DSM-III-R disorders in high school students. J Abnorm Psychol 1996;102:133-144.
7. Rounds-Bryant JL, Kriastiansen PL, Fairbank JA, Hubbard RL: Substance use, mental disorders, abuse, and crime: gender comparisons from a national sample of adolescent drug treatment clinics. J Child Adolesc Subst Abuse 1998;7:19-20.
8. Shrier LA, Harris SK, Kurland M, Knight JR: Substance abuse problems and adolescent psychiatric symptoms among adolescents in primary care. Pediatrics 2003;111:699-705.
9. Whitmore EA, Riggs PD: Developmentally informed diagnostic and treatment considerations in comorbid conditions. Liddle HA, Rowe CL (Eds.). Adolescent substance abuse: research and clinical advances. Cambridge, UK: Cambridge University Press; 2006:264-283.
10. Tarter RE: Etiology of adolescent substance abuse: a developmental perspective. Am J Addict 2002;11:171-191.
11. Tarter RE, Kirisci L, Habeych M, Reynolds M, Vanyukov M: Neurobehavior disinhibition in childhood predisposes boys to substance use disorder by young adulthood. Drug Alcohol Depend 2004;73:121-132.
12. Bukstein OG, Brent DA, Kaminer Y: Comorbidity of substance abuse and other psychiatric disorders in adolescents. Am J Psychiatry 1989;146:1131-1141.
13. Grella CE, Hser Y, Joshi V, Rounds-Bryant J: Drug treatment outcomes for adolescents with comorbid mental and substance use disorders. J Nerv Ment Dis 2001;189:384-392.
14. Deas D, Thomas SE: An overview of controlled studies of adolescent substance abuse treatment. Am J Addict 2001;10:178-189.
15. Geller B, Cooper TB, Sun K, Zimerman B, Frazier J, Williams M, Heath J: Double-blind and placebo-controlled study of lithium for adolescent bipolar disorders with secondary substance dependency. J Am Acad Child Adolesc Psychiatry 1998;37:171-178.
16. Riggs PD, Hall SK, Mikulich-Gilbertson SK, Lohman M, Kayser A: A randomized controlled trial of pemoline for ADHD in substance abusing adolescents. J Am Acad Child Adolesc Psychiatry 2004;43:420-429.
17. Riggs PD, Lohman M, Davies R, Mikulich-Gilbertson S, Klein C, Chapman M, Laudenslager M, Libby A, Orton H, Stover S, Thurstone C: A randomized controlled trial of fluoxetine/placebo and CBT in depressed adolescents with substance use disorders. Abstract/Symposium presented at the 23rd Annual Meeting of the American Academy of Addiction Psychiatry, December 7-11, 2005, Scottsdale, Arizona.
18. Riggs P, Mikulich-Gilbertson S, Lohman M, Klein C, Stover S: A randomized controlled trial of fluoxetine and cognitive behavioral therapy in adolescents with major depression, behavior problems, and substance use disorders. Arch Pediatr Adolesc Med 2007;161(11):1026-1034.
19. Birnbaum HG, Kessler RC, Lowe SW, Secnik K, Greenberg PE, Leong SA, Swensen AR: Costs of attention deficit-hyperactivity disorder (ADHD) in the US: excess costs of persons with ADHD and their family members in 2000. Curr Med Res Opin 2005;21:195-206.
20. Wilens TE: Attention-deficit/hyperactivity disorder and the substance use disorders: the nature of the relationship, subtypes at risk, and treatment issues. Psychiatr Clin North Am 2004;27:283-301.
21. Murphy, K: Psychosocial treatments for ADHD in teens and adults: a practice-friendly review. J Clin Psychol 2005;61:607-619.
22. Kessler RC, Adler L, Barkley R, Biederman J, Conners CK, Demler O, Faraone SV, Greenhill LL, Howes MJ, Secnik K, Spencer T, Ustun TB, Walters EE, Zaslavsky, AM: The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry 2006;163:716-723.
23. American Psychological Association: Diagnostic and statistical manual of mental disorders. Washington, DC: APA; 2000.
24. Carroll KM, Rounsaville BJ: History and significance of childhood attention deficit disorder in treatment-seeking cocaine abusers. Compr Psychiatry 1993;34:75-82.
25. Levin FR, Evans SM, Vosburg SK, Horton T, Brooks D, Ng J: Impact of attention-deficit hyperactivity disorder and other psychopathology on treatment retention among cocaine abusers in a therapeutic community. Addict Behav 2004;29:1875-1882.
26. Wise BK, Cuffe SP, Fischer T: Dual diagnosis and successful participation of adolescents in substance abuse treatment. J Subst Abuse Treat 2001;21:161-165.
27. Barkley RA: Etiologies. Attention-deficit hyperactivity disorder: a handbook for diagnosis and treatment. 3rd ed. New York: Guilford Press; 2006:219-247.
28. Pliszka SR: New developments in psychopharmacology of attention deficit hyperactivity disorder. Expert Opin Investig Drugs 2001;10:1797-1807.
29. Barkley RA, Biederman J: Toward a broader definition of the age-of-onset criterion for attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1997;36:1204-1210.
30. Faraone SV, Biederman J, Spencer T, Mick E, Murray K, Petty C, Adamson JJ, Monuteaux MC: Diagnosing adult attention deficit hyperactivity disorder: are late onset and subthreshold diagnoses valid? Am J Psychiatry 2006;163:1720-1729; quiz 1859.
31. Levin F, Sullivan M, Donovan S: Attention-deficit/hyperactivity disorder and eating disorders. Chevy Chase, MD: American Society of Addiction Medicine; 2003.
32. Mariani JJ, Levin FR: Treatment strategies for co-occurring ADHD and substance use disorders. Am J Addict 2007;16(suppl 1):45-54.
33. Schubiner H, Saules KK, Arfken CL, Johanson CE, Schuster CR, Lockhart N, Edwards A, Donlin J, Pihlgren E: Double-blind placebo-controlled trial of methylphenidate in the treatment of adult ADHD patients with co-morbid cocaine dependence. Exp Clin Psychopharmacol 2002;10:286-294.
34. Levin FR, Evans SM Brooks DJ, Garawi F: Treatment of cocaine dependent treatment seekers with adult ADHD: double-blind comparison of methylphenidate and placebo. Drug Alcohol Depend 2007;87:20-29.
35. Levin FR, Evans SM, Brooks DJ, Kalbag AS, Garawi F, Nunes EV: Treatment of methadone-maintained patients with adult ADHD: double-blind comparison of methylphenidate, bupropion and placebo. Drug Alcohol Depend 2006;81:137-148.
36. Grabowski J, Rhoades H, Schmitz J, Stotts A, Daruzska LA, Creson D, Moeller FG: Dextroamphetamine for cocaine-dependence treatment: a double-blind randomized clinical trial. J Clin Psychopharmacol 2001;21:522-526.
37. Grabowski J, Rhoades H, Stotts A, Cowan K, Kopecky C, Dougherty A, Moeller FG, Hassan S, Schmitz J: Agonist-like or antagonist-like treatment for cocaine dependence with methadone for heroin dependence: two double-blind randomized clinical trials. Neuropsychopharmacology 2004;29:969-981.
38. Levin FR, Evans SM, Kleber HD: Prevalence of adult attention-deficit hyperactivity disorder among cocaine abusers seeking treatment. Drug Alcohol Depend 1998;52:15-25.
39. Weisler RH, Biederman J, Spencer TJ, Wilens TE, Faraone SV, Chrisman AK, Read SC, Tulloch SJ: Mixed amphetamine salts extended-release in the treatment of adult ADHD: a randomized, controlled trial. CNS Spectr 2006;11:625-639.
40. Levin FR, Brooks DJ, Bisaga A, Raby W, Rubin E, Aharonovich E, Nunes EV: Severity of dependence and motivation for treatment: comparison of marijuana- and cocaine-dependent treatment seekers. J Addict Dis 2006;25:33-41.
41. Schubiner H, Tzelepis A, Milberger S, Lockhart N, Kruger M, Kelley BJ, Schoener EP: Prevalence of attention-deficit/hyperactivity disorder and conduct disorder among substance abusers. J Clin Psychiatry 2000;61:244-251.
42. McCabe SE, Knight JR, Teter CJ, Wechsler H: Non-medical use of prescription stimulants among US college students: prevalence and correlates from a national survey. Addiction 2005;100:96-106.
43. McCabe SE, Teter CJ, Boyd CJ, Guthrie SK: Prevalence and correlates of illicit methylphenidate use among 8th, 10th, and 12th grade students in the United States, 2001. J Adolesc Health 2004;35:501-504.
44. Teter CJ, McCabe SE, Cranford JA, Boyd CJ, Guthrie SK: Prevalence and motives for illicit use of prescription stimulants in an undergraduate student sample. J Am Coll Health 2005;53:253-262.
45. Wilens TE, Gignac M, Swezey A, Monuteaux MC, Biederman J: Characteristics of adolescents and young adults with ADHD who divert or misuse their prescribed medications. J Am Acad Child Adolesc Psychiatry 2006;45:408-414.
46. Kollins SH, Rush CR, Pazzaglia PJ, Ali JA: Comparison of acute behavioral effects of sustained-release and immediate-release methylphenidate. Exp Clin Psychopharmacol 1998;6:367-374.
47. Spencer TJ, Faraone SV, Michelson D, Adler LA, Reimherr FW, Glatt SJ, Biederman J: Atomoxetine and adult attention-deficit/hyperactivity disorder: the effects of comorbidity. J Clin Psychiatry 2006;67:415-420.
48. Turner DC, Clark L, Dowson J, Robbins TW, Sahakian BJ: Modafinilimproves cognition and response inhibition in adult attention deficit/hyperactivity disorder. Biol Psychiatry 2004;55:1031-1034.
49. Stevenson CS, Whitmont S, Bornholt L, Livesey D, Stevenson RJ: A cognitive remediation programme for adults with attention deficit hyperactivity disorder. Aust N Z J Psychiatry 2002;36:610-616.
50. Safren SA: Cognitive-behavioral approaches to ADHD treatment in adulthood. J Clin Psychiatry 2006;67(Suppl 8):46-50.
51. Green AI: Treatment of schizophrenia and comorbid substance abuse: pharmacologic approaches. J Clin Psychiatry 2006;67(Suppl 7):31-35; quiz 36-37.
52. Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, Goodwin FK: (1990). Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990;264:2511-2518.
53. Green AI, Noordsy DL, Brunette MF, O'Keefe C: Substance abuse and schizophrenia: pharmacotherapeutic intervention. J Subst Abuse Treat 2008;34(1):61-71.
54. Green AI, Drake RE, Brunette MF, Noordsy DL: Schizophrenia and co-occurring substance use disorder. Am J Psychiatry 2007;164(3):402-408.
55. Khantzian EJ: The self-medication hypothesis of substance use disorders: a reconsideration and recent applications. Harv Rev Psychiatry 1997;4(5):231-244.
56. Siris SG: Pharmacological treatment of substance-abusing schizophrenic patients. Schizophr Bull 1990;16: 111-122.
57. Green AI, Zimmet SV, Strous RD, Schildkraut JJ: Clozapine for comorbid substance use disorder and schizophrenia: do patients with schizophrenia have a reward-deficiency syndrome that can be ameliorated by clozapine? Harv Rev Psychiatry 1999;6:287-296.
58. Roth RM, Brunette MF, Green AI: Treatment of substance use disorders in schizophrenia: a unifying neurobiological mechanism? Curr Psychiatry Rep 2005;7:283-291.
59. Chambers AR, Krystal JH, Self DW: A neurobiological basis for substance abuse comorbidity in schizophrenia. Biol Psychiatry 2001;50:71-83.
60. Svensson TH, Mathe JM, Andersson JL, Nomikos GG, Hildebrand BE, Marcus M: Mode of action of atypical neuroleptics in relation to the phencyclidine model of schizophrenia: role of 5-HT2 receptor and alpha 1-adrenoceptor antagonism. J Clin Psychopharmacol 1995;15(1 Suppl 1):11S-18S.
61. Knutson B, Fong GW, Bennett SM, Adams CM, Hommer DA: Region of mesial prefrontal cortex tracks monetarily rewarding outcomes: characterization with rapid event-related fMRI. Neuroimage 2003;18:263-272.
62. Juckel G, Schlagenhauf F, Koslowski M, Wustenberg T, Villringer A, Knutson B, Wrase J, Heinz A: Dysfunction of ventral striatal reward prediction in schizophrenia. Neuroimage 2006;29:409-416.
63. Wint D, Dreher J, Furman D, Koch P, Kohn P, Egan M, Weinberger D, Berman KF: Altered cerebral processing of reward uncertainty in patients with schizophrenia while medication-free and on atypical neuroleptics. Neuropsychopharmacology 2005;30(Suppl 1):S262.
64. Drake RE, Musered KT, Brunette MF, McHugo GJ: A review of treatments for people with severe mental illnesses and co-occurring substance use disorders. Psychiatr Rehab J 2004;27:360-374.
65. Mueser KT, Noordsy DL, Drake RE, Fox L: Integrated treatment for dual disorders: a guide to effective practice. New York: Guilford Press; 2003.
66. McEvoy JP, Freudenreich O, Levin ED, Rose JE: Haloperidol increases smoking in patients with schizophrenia. Psychopharmacology 1995;119:124-126.
67. Green AI: Pharmacotherapy for schizophrenia and co-occurring substance use disorders. Neurotox Res 2007;11:1-6.
68. McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, Swartz MS, Perkins DO, Keefe RS, Davis CE, Severe J, Hsiao JK: CATIE Investigators: Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 2006;163:600-610.
69. Buckley PF: Substance abuse in schizophrenia: a review. J Clin Psychiatry 1998;59(Suppl 3):26-30.
70. Ziedonis DM, Smelson D, Rosenthal RN, Batki SL, Green AI, Henry RJ, Montoya I, Parks J, Weiss RD: Improving the care of individuals with schizophrenia and substance use disorders: consensus recommendations. J Psychiatr Pract 2005;11:315-339.
71. Green AI, Chau DT, Keung WM, Dawson R, Mesholam RI, Schildkraut JJ: Clozapine reduces alcohol drinking in Syrian golden hamsters. Psychiatry Res 2004;128:9-20.
72. Petrakis IL, Nich C, Ralevski E: Psychotic spectrum disorders and alcohol abuse: a review of pharmacotherapeutic strategies and a report on the effectiveness of naltrexone and disulfiram. Schizophr Bull 2000;32:644-654.
73. Petrakis IL, O'Malley S, Rounsaville B, Poling J, McHugh-Strong C, Krystal JH: Naltrexone augmentation of neuroleptic treatment in alcohol abusing patients with schizophrenia. Psychopharmacology (Berl) 2004;172:291-297.
74. George TP, Vessicchio JC, Termine A, Bregartner TA, Feingold A, Rounsaville BJ, Kosten TR: A placebo controlled trial of bupropion for smoking cessation in schizophrenia. Biol Psychiatry 2002;52:53-61.
75. Huguelet P, Morand-Collomb S: Effect of topiramate augmentation on two patients suffering from schizophrenia or bipolar disorder with comorbid alcohol abuse. Pharmacol Res 2005;52:392-394.
76. Ziedonis DM, Richardson T, Lee E, Petrakis I, Kosten T: Adjunctive desipramine in the treatment of cocaine abusing schizophrenics. Psychopharmacol Bull 1992;28:309-314.
77. Godley SH, Dennis ML, Godley MD, Funk RR: Thirty month relapse trajectory cluster groups among adolescents discharged from outpatient treatment. Addiction 2004;99(Suppl 2):129-139.
78. Newton T, Roache JD, De La Garza R 2nd, Fong T,Wallace Cl, Li Sh, Elkashef A, Chiang N, Kahn R: Bupropion reduces methampheteamine-induced subjective effects and cue-induced craving. Neuropsychopharmacology 2006;31:1537-2534.